Heart Failure Research

Heart failure, also known as congestive heart failure or CHF, is an inability of the heart to pump sufficient blood around the body.Heart failure typically occurs secondary to an existing pathology that alters cardiac function. Examples of syndromes that can precede heart failure include myocardial infarction, arrhythmia or infection. These can also cause dilated cardiomyopathy, a condition which accounts for approximately one third of all cases of heart failure. The pathogenesis of heart failure is cyclical and progressive; endogenous mechanisms, which are activated during heart failure in an attempt to counteract the symptoms, actually worsen cardiac function. Cardiac dysfunction, either systolic or diastolic, triggers a decrease in stroke volume and a resultant increase in cardiac output. In healthy individuals the body responds to decreases in cardiac output by initiating the renin-angiotensin-aldosterone system (RAAS) to promote fluid retention, and also by activating the sympathetic nervous system to cause peripheral vasoconstriction. Under normal circumstances this counteracts the imbalance in stroke volume, restoring cardiac output to normal levels. In patients with heart failure the increase in blood volume, together with the heightened peripheral resistance and elevated levels of circulating catecholamines, causes an increased load on the already weakened ventricles with each contraction, and the stroke volume does not return to normal levels. Repeated cycles of this process further weaken the ventricle walls, prompting ventricular hypertrophy and a decreased force of contraction.

Heart Failure Research Products Targets

Products for Heart Failure Research - Page 5

  1. Cat.No. Product Name Information/Activity
  2. BCC6797 Efaroxan hydrochloride 89197-00-2 Efaroxan hydrochloride chemical structure
  3. BCC6798 Idazoxan hydrochloride Idazoxan hydrochloride (RX 781094 hydrochloride) is an α2-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like drugs (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism. Idazoxan hydrochloride chemical structure
  4. BCC6875 Imiloxan hydrochloride 81167-22-8 Imiloxan hydrochloride chemical structure
  5. BCC7449 JP 1302 dihydrochloride JP1302 dihydrochloride is a selective, high affinity antagonist of the alpha2C-adrenoceptor (α2C-adrenoceptor), with a Kb value (antagonist activity) of 16 nM and a Ki (binding affinity) value of 28 nM. JP 1302 dihydrochloride chemical structure
  6. BCC4923 Mirtazapine Mirtazapine is a 5-HT receptor inhibitor. Mirtazapine is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent by blocking 5-HT2 and 5-HT3 receptors. Mirtazapine chemical structure
  7. BCC6834 Rauwolscine hydrochloride Rauwolscine hydrochloride is a potent and specific α2 adrenergic receptor antagonist with a Ki of 12 nM. Rauwolscine hydrochloride chemical structure
  8. BCC6876 RS 79948 hydrochloride 186002-54-0 RS 79948 hydrochloride chemical structure
  9. BCC7021 RX 821002 hydrochloride 109544-45-8 RX 821002 hydrochloride chemical structure
  10. BCC6208 S 32212 hydrochloride 847871-78-7 S 32212 hydrochloride chemical structure
  11. BCC7795 SKF 86466 hydrochloride 86129-54-6 SKF 86466 hydrochloride chemical structure

Items 41 to 50 of 148 total